CD70 is a novel therapeutic target for EGFR mutant NSCLC with acquired, EMT-associated EGFR TKI resistance

被引：0

作者：

Nilsson, Monique B. ^{[1
]}

Yang, Yan ^{[1
]}

Patel, Sonia ^{[1
]}

Heeke, Simon ^{[1
]}

Le, Xiuning ^{[1
]}

Aruguman, Thiru ^{[1
]}

Robichaux, Jacqulyne ^{[1
]}

Yu, Xiaoxing ^{[1
]}

Poteete, Alissa ^{[1
]}

Ren, Xiaoyang ^{[1
]}

Diao, Lixia ^{[1
]}

Shen, Li ^{[1
]}

Wang, Qi ^{[1
]}

Zhang, Fahao ^{[1
]}

Clemente, Leticia Campos ^{[1
]}

Soto, Luisa Solis ^{[1
]}

Shi, Chunhua ^{[1
]}

Tran, Hai ^{[1
]}

Bock, Jason ^{[1
]}

Wang, Jing ^{[1
]}

Wistuba, Ignacio I. ^{[1
]}

Minna, John D. ^{[2
]}

Heymach, John V. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Univ Texas SouthWestern Med Ctr, Dallas, TX USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1827

引用

页数：1

共 50 条

[41] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Izumi, Hiroto
Kanda, Rina
Murakami, Yuichi
Morimoto, Yasuo
Ono, Mayumi
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[42] Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation
Izumi, Hiroto
Kanda, Rina
Murakami, Yuichi
Morimoto, Yasuo
Ono, Mayumi
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[43] Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
Lee, Eun Ji
Oh, Seung Yeon
Lee, You Won
Ju Young, Kim
Kim, Min-Je
Kim, Tae Ho
Lee, Jii Bum
Hong, Min Hee
Lim, Sun Min
Baum, Anke
Woelflingseder, Lydia
Engelhardt, Harald
Petronczki, Mark
Solca, Flavio
Yun, Mi Ran
Cho, Byoung Chul
CLINICAL CANCER RESEARCH, 2024, 30 (08) : 1582 - 1594
[44] ACQUIRED RESISTANCE IN NSCLC WITH EGFR MUTATION TREATED WITH TKI'S: SINGLE CENTER EXPERIENCE AND TREATMENT OUTCOME
Griesinger, Frank
Halbfass, Volker
Conradi, Imme
Hallas, Cora
Henke, R. P.
Falk, Markus
Tiemann, Markus
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S798 - S799
[45] Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI)
Goldberg, Sarah B.
Oxnard, Geoffrey R.
Digumarthy, Subba
Muzikansky, Alona
Jackman, David Michael
Lennes, Inga Tolin
Sequist, Lecia V.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[46] Acquired resistance to gefitinib is associated with cancer stem-like phenotype and EMT in EGFR mutant lung adenocarcinoma.
Lim, Sun Min
Kim, Hyun Jung
Ban, Young Ho
Ha, Sang Jun
Cho, Byoung Chui
CANCER RESEARCH, 2013, 73 (08)
[47] PAI1, a β catenin transcriptional target, serves as a surrogate biomarker to predict EGFR TKI mediated drug persistence in EGFR mutant NSCLC
Arasada, Rajeswara Rao
Wang, Walter
Suman, Shankar
Carbone, David Paul
CANCER RESEARCH, 2019, 79 (13)
[48] Acquired resistance in NSCLC with EGFR mutation treated with TKI's: Single center experience and treatment outcome
Griesinger, F.
Halbfass, V
Conradi, I
Hallas, C.
Henke, R-P
Falk, M.
Tiemann, M.
ONKOLOGIE, 2013, 36 : 30 - 31
[49] Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
Falk, Markus
Schatz, Stefanie
Reich, Fabian P. M.
Schmidt, Stefanie
Galster, Marco
Tiemann, Markus
Ficker, Joachim H.
Brueckl, Wolfgang M.
CURRENT ONCOLOGY, 2023, 30 (10) : 8865 - 8871
[50] Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
Jiang, Tao
Li, Aiwu
Su, Chunxia
Li, Xuefei
Zhao, Chao
Ren, Shengxiang
Zhou, Caicun
Zhang, Jun
ONCOTARGET, 2017, 8 (37) : 62648 - 62657

← 1 2 3 4 5 →